Bioline Rx Ltd (BLRX)

NASDAQ

$2.83

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company is headquartered in Hevel Modi'in, Israel.

Sector:

Industry:

68 analysts

Buy

Target: $17.50 (+518.37%)

Market Cap

$13M

P/B Ratio

0.76

Free Cash Flow Yield

-58.62%

Beta (5Y)

0.94

Adjust inflation

Log

Valuation

Market Cap$13M

Forward P/E93.46

P/S9.56

P/B0.76

Profitability

Total Revenue (TTM)$1.40M

Gross Profit (TTM)$1.11M

EBITDA-$8.20M

Operating Margin-630%

EPS-$2.15

Financial Health

Debt-to-Equity54.4%

Free Cash Flow Yield-58.62%

Growth & Risk

EPS 5Y CAGR-12.74%

FCF 5Y CAGR-19.20%

Beta (5Y)0.94

Sharpe Ratio-0.57